Did Pfizer’s exit in the ’90s cost them a GLP-1 stronghold?

GLP-1 analogs, medications that lower blood sugar levels and promote weight loss, have seen significant growth in recent years. However, Pfizer may have missed the opportunity to be a part of this growth. Despite promising early results, Pfizer’s previous partnership with MetaBio failed to generate a marketable product. Pfizer’s current candidate, danuglipron, is undergoing studies and faces fierce competition from existing products on the market.